You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 1, January 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE FIFTH ANNUAL MEETING OF THE SURGICAL INFECTION SOCIETY, NEW ORLEANS, APRIL 29 TO APRIL 30, 1985-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Immunotherapy of Gram-negative Bacterial Sepsis

A Single Murine Monoclonal Antibody Provides Cross-Genera Protection

David L. Dunn, MD, PhD; David C. Ewald; Naresh Chandan, MS; Frank B. Cerra, MD

Arch Surg. 1986;121(1):58-62.


Abstract

• Previous experimental and clinical studies have demonstrated the ability of polyclonal antibody directed against the core lipopolysaccharide (LPS)-lipid A component of endotoxin to reduce mortality. We sought to characterize the ability of a single murine monoclonal IgG, antibody (8A1 MAb) to react to a variety of gram-negative microorganisms, to promote phagocytosis, and to provide protection during experimental murine sepsis. The 8A1 MAb reacted to various gram-negative bacterial whole cell and LPS antigens examined by enzyme-linked immunosorbent assay. Reactivity was highest to Salmonella minnesota Re LPS and lipid A. Phagocytosis was promoted by this monoclonal antibody to several gram-negative bacteria, except Pseudomonas aeruginosa. The 8A1 MAb (2 mg per mouse) enhanced survival during bacteremia due to either Escherichia coli 0111:B4 or Klebsiella pneumoniae, and during endotoxemia due to all types of LPS examined except P aeruginosa. We concluded that a single MAb with anti—lipid A specificity was cross reactive in vitro and cross protective in vivo. A clinical trial comparing polyclonal and monoclonal antibody in high-risk septic patients seems warranted.

(Arch Surg 1986;121:58-62)



Author Affiliations

From the Department of Surgery, University of Minnesota, Minneapolis.


Footnotes

Accepted for publication Oct 1, 1985.

Read before the Fifth Annual Meeting of the Surgical Infection Society, New Orleans, April 29, 1985.

Reprint requests to Box 242 Mayo Memorial Bldg, 420 Delaware St SE, University of Minnesota, Minneapolis, MN 55455 (Dr Dunn).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during Gram-negative bacterial sepsis
Greisman and Johnston
Innate Immunity 1997;4:123-153.
ABSTRACT  

Decreased Tumor Necrosis Factor Production During the Initial Stages of Infection Correlates With Survival During Murine Gram-negative Sepsis
Mayoral et al.
Arch Surg 1990;125:24-28.
ABSTRACT  

Protective Capacity of Polyclonal and Monoclonal Antibodies Directed Against Endotoxin During Experimental Sepsis
Dunn et al.
Arch Surg 1988;123:1389-1393.
ABSTRACT  

Posttraumatic Multisystem Organ Failure
DeCamp and Demling
JAMA 1988;260:530-534.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.